V. Torri

发表

Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study).

V. Torri, A. Bardelli, E. Maiello, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma.

R. Labianca, V. Torri, F. Landoni, 2003, European journal of cancer.

Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group

P. A. Gardner, A. Caraceni, S. Boriani, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer?

L. Porcu, M. Garassino, C. Bestvina, 2023, Therapeutic advances in medical oncology.

Cell kinetics of human ovarian cancer with in vivo administration of bromodeoxyuridine.

V. Torri, G. Mazzini, F. Landoni, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data.

M. Parmar, J. Ledermann, I. Vergote, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Malignant peritoneal mesothelioma: a multicenter study on 81 cases.

V. Torri, S. Siena, M. Cinquini, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

S. Litière, A. Cesne, H. Joensuu, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study

V. Torri, M. Cazzaniga, A. Zeppellini, 2014, International journal of breast cancer.

HER2 loss in HER2‐positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research

E. Vasile, V. Torri, L. Antonuzzo, 2016, International journal of cancer.

Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies

S. Cosimo, G. Bregni, G. Galli, 2015, Clinical and Translational Oncology.

378PDISEASE PROGRESSION PATTERN IN METASTATIC BREAST CANCER PATIENTS (MBC) TREATED WITH ANTI-HER2 THERAPIES.

V. Torri, F. D. De Braud, S. Cosimo, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis

A. Lissoni, A. Garbi, R. Fossati, 2008, British Journal of Cancer.